spacer
home > ebr > winter 2018 > fight against resistance
PUBLICATIONS
European Biopharmaceutical Review

Fight Against Resistance

Microbial resistance to antibiotics is rising. Keiji Fukuda at the WHO has described antimicrobial resistance (AMR) as a major threat to global public health, stating “Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill” (1). AMR is a natural and inevitable phenomenon, an outcome of natural selection; bacteria always have evolved to resist threats to their survival and will continue to do so. AMR cannot be completely prevented, but urgent action must be taken to curtail it and minimise its impact on global health.

Excessive and inappropriate use of antibiotics and antimicrobials more widely – combined with inadequate infection control and poor hygiene – are the main factors contributing to the spread of resistance, according to the European Commission’s statement on AMR (2). Decades of over-prescription and off-prescription use, in both humans and animals, have exacerbated the problem, and development of new antibiotics has all but stalled, with far fewer new drugs being licensed in the last couple of decades than in the early and mid-20th century.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michele Barbour is Chief Executive Officer of Pertinax Pharma. Pertinax technology was developed by her research group at the University of Bristol, UK, where she is Reader in biomaterials and Deputy Head of Bristol Dental School, UK. Michele is the author of over 50 peer-reviewed publications and a leading textbook. She founded Pertinax Pharma in 2015 to commercialise the technology that allows the controlled and sustained release of the antiseptic chlorhexidine.
spacer
Dr Michele Barbour
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for pharmaceutical and medical device applications

Novo Nordisk Pharmatech A/S has entered into an agreement with Signet Chemical Corporation Pvt. Ltd. for the distribution of their pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement